Biopharmaceutical company focused on developing treatments for neuropsychiatric disorders.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapeutic treatments for a range of brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
Central to its portfolio is navacaprant (NMRA-140), an innovative once-daily oral kappa opioid receptor antagonist currently undergoing phase 3 clinical trials. Navacaprant aims to address major depressive disorder by targeting specific pathways associated with this condition.
The company is also advancing other promising candidates in its pipeline. NMRA-511 is in phase 1 clinical trials targeting agitation associated with dementia due to Alzheimer's disease, while NMRA-266 is undergoing phase 1 clinical trials for the treatment of schizophrenia and other neuropsychiatric disorders.
Neumora Therapeutics, Inc. is actively engaged in preclinical development of several potential therapies. These include NMRA-NMDA for schizophrenia treatment, NMRA-CK1d, a CK1d inhibitor program for amyotrophic lateral sclerosis, NMRA-NLRP3 for specific neurodegenerative conditions, and NMRA-GCase for Parkinson's disease management.
Founded in 2019 and headquartered in Watertown, Massachusetts, Neumora Therapeutics, Inc. was formerly known as RBNC Therapeutics, Inc. before rebranding in October 2021. The company remains committed to advancing innovative treatments that aim to improve the lives of patients affected by challenging neurological conditions.